Target Name: CCSER2
NCBI ID: G54462
Review Report on CCSER2 Target / Biomarker Content of Review Report on CCSER2 Target / Biomarker
CCSER2
Other Name(s): CCSER2 variant 2 | Coiled-coil serine rich protein 2, transcript variant 2 | Coiled-coil serine-rich protein 2 | GCAP14 | protein GCAP14 homolog | Gcap14 | FAM190B | coiled-coil serine rich protein 2 | FLJ14262 | Protein GCAP14 homolog | Granule cell antiserum positive 14 | protein FAM190B | Serine-rich coiled-coil domain-containing protein 2 | bA486O22.1 | family with sequence similarity 190, member B | CCSE2_HUMAN | Serine-rich coiled-coil domain-containing protein 2 (isoform 2) | KIAA1128

CCSER2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive and terminal conditions that affect the nervous system and can lead to a range of symptoms and disabilities. These conditions are often associated with the immune system, which becomes abnormally active and leads to inflammation. Therefore, it is crucial to identify potential drug targets and biomarkers that can treat these diseases. In this article, we discuss CCSER2, a protein that has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases.

CCSER2: CCSER2 is a type-I transmembrane protein that is expressed in various tissues and cells in the body. It is involved in the regulation of cell signaling pathways, including T cell signaling, and has been implicated in the development and progression of neurodegenerative diseases.

Potential Drug Target:

The immune system plays a crucial role in the development of inflammatory neurodegenerative diseases. When the immune system becomes abnormally active, it can cause damage to the nervous system and contribute to the development of these diseases. CCSER2 has been shown to be involved in the regulation of immune cell function, and it has been linked to the development of neurodegenerative diseases. Therefore, CCSER2 may be a potential drug target for the treatment of inflammatory neurodegenerative diseases.

Biomarker:

CCSER2 has also been identified as a potential biomarker for the treatment of inflammatory neurodegenerative diseases. The development of neurodegenerative diseases is often associated with the production of pro-inflammatory cytokines, which can contribute to the inflammation that occurs in these diseases. CCSER2 has been shown to be involved in the production and regulation of these cytokines, which may make it an attractive biomarker for the treatment of inflammatory neurodegenerative diseases.

Pathology

Neurodegenerative diseases are characterized by the progressive loss of neural cells and the formation of aggregates of neurodegenerate proteins. These diseases can cause a range of symptoms, including cognitive decline, motor neuron dysfunction, and behavioral changes. The development of these diseases is often associated with the production of pro-inflammatory cytokines, which can contribute to the inflammation that occurs in these diseases.

Modeling

To further understand the role of CCSER2 in the development and progression of neurodegenerative diseases, researchers have used mathematical models to predict the effects of potential drugs on CCSER2 expression and activity. These models have predicted that drugs that can inhibit the activity of CCSER2 may be effective in treating neurodegenerative diseases.

Conclusion

In conclusion, CCSER2 is a protein that has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. The regulation of immune cell function and the production of pro-inflammatory cytokines are key factors in the development and progression of these diseases, and CCSER2 is involved in these processes. Therefore, CCSER2 may be a promising target for the development of new treatments for neurodegenerative diseases.

Protein Name: Coiled-coil Serine Rich Protein 2

Functions: Microtubule-binding protein which might play a role in microtubule bundling

The "CCSER2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCSER2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8